How should an acute SNRI (serotonin‑norepinephrine reuptake inhibitor) overdose be managed?

Management of Acute SNRI Overdose

Immediately discontinue the SNRI, provide aggressive supportive care with benzodiazepines for agitation, and administer cyproheptadine (12 mg initially, then 2 mg every 2 hours for continuing symptoms) for moderate to severe serotonin syndrome, which is the primary life-threatening complication of SNRI overdose. 1

Primary Concern: Serotonin Syndrome

SNRI overdose primarily causes serotonin syndrome, a potentially fatal condition characterized by the clinical triad of:

• Mental status changes (agitation, confusion, delirium)
• Autonomic hyperactivity (hyperthermia, hypertension, tachycardia, diaphoresis)
• Neuromuscular abnormalities (hyperreflexia, clonus, muscle rigidity, myoclonus)

The most diagnostic finding is clonus and hyperreflexia—their presence in the setting of SNRI use essentially establishes the diagnosis 1. Myoclonus occurs in 57% of cases 1.

Immediate Management Algorithm

Step 1: Discontinue the Drug and Assess Severity

• Stop all serotonergic agents immediately
• Assess using Hunter Criteria (higher sensitivity 84% and specificity 97% than older Sternbach criteria) 1
• Recognize that venlafaxine and desvenlafaxine have been associated with overdose fatalities 2, 3

Step 2: Supportive Care (All Cases)

• Benzodiazepines for agitation and to control muscular hyperactivity (first-line for agitation) 1
• IV fluids for autonomic instability
• External cooling for hyperthermia (avoid physical restraints—they worsen isometric contractions, hyperthermia, and lactic acidosis) 1
• Monitor vital signs continuously: blood pressure, heart rate, temperature

Step 3: Pharmacologic Intervention for Moderate to Severe Cases

Cyproheptadine (serotonin-2A antagonist) is the preferred specific treatment 1:

• Adult dosing: 12 mg initially, then 2 mg every 2 hours for continuing symptoms
• Maintenance: 8 mg every 6 hours orally
• Pediatric dosing: 0.25 mg/kg per day
• Can be crushed and given via nasogastric tube (no parenteral form available)

Step 4: Severe Cases (Temperature >41.1°C)

• Emergency sedation
• Neuromuscular paralysis with nondepolarizing agents (vecuronium or rocuronium)
• Intubation and mechanical ventilation
• Avoid succinylcholine due to risk of hyperkalemia and worsening rhabdomyolysis 1

Step 5: Manage Hemodynamic Instability

• Use short-acting agents: esmolol for tachycardia, nitroprusside for hypertension
• Use direct-acting sympathomimetics (phenylephrine, norepinephrine, epinephrine) for hypotension
• Avoid indirect agents like dopamine—they may overshoot desired effects due to altered catecholamine metabolism 1

Critical Monitoring Parameters

Obtain the following based on severity:

• Complete blood count (leukocytosis common)
• Creatine kinase (rhabdomyolysis)
• Metabolic panel (renal function, electrolytes)
• Arterial blood gas (metabolic acidosis)
• Hepatic transaminases (liver dysfunction)
• Coagulation studies (disseminated intravascular coagulation in severe cases)
• ECG (dysrhythmias)
• Urinalysis (myoglobinuria)

Key Clinical Pitfalls

1. Don't miss mild cases: Not all patients present with the full triad. A patient may be afebrile but still have tachycardia and hypertension 1

2. Rapid deterioration: Serotonin syndrome can progress to death in approximately 6 hours after ingestion 3. Mortality rate is approximately 11% 1

3. Dose-response is weak: In a large study of 1,978 overdoses, the probability of serotonin toxicity increased only slightly with dose (12.5% at therapeutic dose vs 19% at 420 DDDs) 4. This means even modest overdoses can be dangerous.

4. Co-ingestions matter significantly:

   • MAOIs increase risk 33-fold (probability jumps to 83%) 4
   • Olanzapine or risperidone decrease risk 2-6 fold (5-HT2A antagonism protective) 4
   • Benzodiazepines are commonly co-ingested (21% of cases) 4

5. Differential diagnosis: Distinguish from neuroleptic malignant syndrome (lead-pipe rigidity, bradyreflexia), anticholinergic syndrome (dry skin, mydriasis, absent bowel sounds), and malignant hyperthermia (requires anesthetic exposure) 1

6. Fever mechanism: Hyperthermia is secondary to muscular hyperactivity, not hypothalamic dysfunction—treat by controlling muscle activity, not antipyretics 1

Prognosis and Disposition

• Severe cases are characterized by rhabdomyolysis, metabolic acidosis, renal failure, seizures, and disseminated intravascular coagulation 1
• Approximately 25% require ICU admission with intubation and mechanical ventilation 1
• Most cases resolve within 24 hours with appropriate treatment if serotonergic agents are discontinued
• All SNRI overdoses warrant hospital admission for monitoring given the risk of rapid deterioration and the association of venlafaxine/desvenlafaxine with fatal outcomes 2, 3